Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe Sells 18,959 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $25.77, for a total transaction of $488,573.43. Following the completion of the sale, the chief financial officer now directly owns 132,578 shares of the company’s stock, valued at $3,416,535.06. The trade was a 12.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98.
• On Monday, October 14th, Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09.
• On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The shares were sold at an average price of $19.96, for a total transaction of $196,965.28.

Hims & Hers Health Trading Up 5.3 %

NYSE HIMS opened at $27.60 on Tuesday. The stock has a market cap of $6.03 billion, a P/E ratio of 62.73 and a beta of 1.25. The company’s fifty day simple moving average is $25.78 and its 200-day simple moving average is $21.26. Hims & Hers Health, Inc. has a 52 week low of $8.09 and a 52 week high of $35.02.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the prior year, the company posted ($0.04) EPS. The firm’s revenue for the quarter was up 77.1% on a year-over-year basis. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of recent analyst reports. Piper Sandler restated a “neutral” rating and issued a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. TD Cowen restated a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their price target for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. Finally, Morgan Stanley assumed coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $22.80.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently bought and sold shares of the business. Main Management ETF Advisors LLC purchased a new position in shares of Hims & Hers Health during the 3rd quarter valued at approximately $672,000. Robeco Institutional Asset Management B.V. acquired a new stake in Hims & Hers Health in the third quarter valued at $604,000. Carnegie Investment Counsel bought a new position in Hims & Hers Health during the 3rd quarter valued at $5,531,000. Royce & Associates LP grew its holdings in Hims & Hers Health by 17.0% during the 3rd quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock worth $6,281,000 after acquiring an additional 49,500 shares in the last quarter. Finally, Versor Investments LP acquired a new position in Hims & Hers Health during the 3rd quarter worth $634,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.